February 17, 2010 (FinancialWire) — Novavax, Inc.’s (NASDAQ: NVAX) board of directors has elected Stanley Erck as Executive chairman.

Erck previously served as president and chief executive officer of Iomai, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate.

Prior to Iomai, Erck served as president and chief executive officer of Procept; as vice president of Corporate Development at Integrated Genetics, and in management positions at Baxter International.

Novavax is a clinical-stage biotechnology company creating novel vaccines to address a range of infectious diseases worldwide, including H1N1, using proprietary virus-like-particle technology.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.